Asco 2025 · Posters · Terapias en desarrollo · María Gion, MD, PhD Volver

Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.

Abstract: TPS3172
Poster Bd #: 479b
Descargar Poster

María Gion, MD, PhD

IOB Madrid, Institute of Oncology, Hospital Beata María Ana

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo